Annovis Bio Inc. - notizie pubblicate 168 - letture 3.113


Annovis Bio Inc.

ANNOVIS BIO INC.

Material Event - Form 8-K

Item 8.01 other events. as previously announced in its current report on form 8-k filed with the securities and exchange commission on april 26, 2024, on april 25, 2024, annovis bi ...

02.05.2024
Annovis Bio Inc.

ANNOVIS BIO INC.

Supplemental Prospectus - Form 424B5

Tm2412762-1_424b5 - none - 6.5156446s table of contents filed pursuant to rule 424(b)(5) registration statement no. 333-276814 prospectus supplement (to prospectus dated february 1 ...

01.05.2024
Annovis Bio Inc.

ANNOVIS BIO INC.

Additional Proxy Soliciting Materials - Form DEFA14A

United states securities and exchange commission washington, d.c. 20549 schedule 14a proxy statement pursuant to section 14(a) of the securities exchange act of 1934 (amendment no. ...

29.04.2024
Annovis Bio Inc.

ANNOVIS BIO INC.

Proxy Statement - Form DEF 14A

United states securities and exchange commission washington, d.c. 20549 schedule 14a proxy statement pursuant to section 14(a) of the securities exchange act of 1934 (amendment no. ...

29.04.2024
Annovis Bio Inc.

ANNOVIS BIO INC.

Annual Report - Form ARS

The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer annovis bio inc. published this conten ...

29.04.2024
Annovis Bio Inc.

ANNOVIS BIO INC.

April 29, 2024Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease

The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer annovis bio inc. published this conten ...

29.04.2024
Annovis Bio Inc.

ANNOVIS BIO INC.

Material Agreement - Form 8-K

Item 1.01 entry into a material definitive agreement. on april 25, 2024, annovis bio, inc., a delaware corporation (the "company"), entered into a common stock purchase a ...

26.04.2024
Annovis Bio Inc.

ANNOVIS BIO INC.

ANNOVIS BIO PROVIDES CORPORATE UPDATES AND REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS - Form 8-K

Annovis bio provides corporate updates and reports fourth quarter and full year 2023 financial results tue, 02 apr 2024 malvern, pa., april 02, 2024 (globe newswire) -- annovis bio ...

03.04.2024
Annovis Bio Inc.

ANNOVIS BIO INC.

April 2, 2024Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

Tue, 02 apr 2024 malvern, pa., april 02, 2024 (globe newswire) -- annovis bio, inc. (nyse: anvs) ("annovis" or the "company"), a clinical-stage drug platform co ...

02.04.2024
Annovis Bio Inc.

ANNOVIS BIO INC.

Annual Report for Fiscal Year Ending December 31, 2023 (Form 10-K)

Table of contents united states securities and exchange commission washington, d.c. 20549 form 10-k ☒ annual report pursuant to section 13 or 15(d) of the securities exchange act ...

29.03.2024
Annovis Bio Inc.

ANNOVIS BIO INC.

Material Event - Form 8-K

Item 8.01 other information. as disclosed on the form 8-k filed with the securities and exchange commission (the "commission") on march 21, 2024, annovis bio, inc. (the & ...

22.03.2024
Annovis Bio Inc.

ANNOVIS BIO INC.

Supplemental Prospectus - Form 424B5

Filed pursuant to rule 424(b)(5) registration no. 333-276814 prospectus supplement (to prospectus dated february 12, 2024) 316,455 shares of common stock we are offering 316,455 sh ...

22.03.2024
Annovis Bio Inc.

ANNOVIS BIO INC.

Material Agreement - Form 8-K

Item 1.01 entry into a material definitive agreement. on march 21, 2024, annovis bio, inc. (the "company") entered into a securities purchase agreement (the "purchas ...

21.03.2024
Annovis Bio Inc.

ANNOVIS BIO INC.

ANNOVIS BIO PROVIDES DATA ANNOUNCEMENT UPDATE FOR THE PHASE II/III STUDY OF BUNTANETAP IN ALZHEIMER’S DISEASE - Form 8-K

Annovis bio provides data announcement update for the phase ii/iii study of buntanetap in alzheimer's disease malvern, pa.-march 20, 2024 -- annovis bio, inc. (nyse: anvs), a clini ...

20.03.2024
Annovis Bio Inc.

ANNOVIS BIO INC.

March 20, 2024Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease

Wed, 20 mar 2024 malvern, pa., march 20, 2024 (globe newswire) -- annovis bio, inc. (nyse: anvs), a clinical-stage drug platform company developing novel therapies for neurodegener ...

20.03.2024
Condividi